Cancer Causes & Control

, Volume 20, Issue 1, pp 115–119 | Cite as

Acral lentiginous melanoma presents distinct clinical profile with high cancer susceptibility

  • Eduardo NagoreEmail author
  • Carolina Pereda
  • Rafael Botella-Estrada
  • Celia Requena
  • Carlos Guillén
Brief Report



Acral lentiginous melanoma (ALM) is a distinct histological variant of cutaneous melanoma that presents a genomic profile different from the other variants. Our aim was to explore the distinctive clinical, pathological, and epidemiological characteristics of ALM.

Patients and methods

A series of 978 patients with primary cutaneous melanoma was selected from a single referral center. Among these, 79 were located on acral sites and 46 presented an ALM. This group was compared with a group composed of 932 patients with the remaining three most frequent cutaneous melanoma variants.


The ALM differed significantly from other variants: in an older age at diagnosis (65.52 vs. 51.79 years), a lower number of common (88.2 vs. 55.8%) and atypical nevi (95.0 vs. 80.2%), a predisposing genetic trait to cancer (22.2 vs. 7.1% had a personal history of other non-cutaneous malignancies and 58.1 vs. 36.4% had at least one first degree relative with non-cutaneous neoplasia) and lower number of sunburns (88.2 vs. 47.4% remembered none). Also, the tumors were thicker (mean of 2.94 vs. 2.03 mm), more frequently ulcerated (74.2 vs. 23.9%) and with perineural invasion (8.0 vs. 1.5%), had lower degree of inflammatory infiltrate (36.8 vs. 7.5% was absent) and were less frequently associated with a previous melanocytic lesion (8.3 vs. 32.6%). Differences were kept even after age-adjusted analyses.


Our results, from a clinical and epidemiological point of view, support recent data on genetic characterization of melanomas. In comparison with the other frequent variants we have shown that ALM has some important differences which emphasize that it is a distinct entity more probably related to certain cancer susceptibility but unrelated to familial melanoma, tendency to developing nevus or sun exposure.


Acral lentiginous melanoma Melanoma Epidemiology Histology 



The authors thank Dr. Geoffrey Hall, F.R.C.P (UK) for his invaluable help with the English style.


  1. 1.
    Kabbarah O, Chin L (2005) Revealing the genomic heterogeneity of melanoma. Cancer Cell 8:439–441PubMedCrossRefGoogle Scholar
  2. 2.
    Halpern AC, Marghoob AA, Sober AJ (2003) Clinical characteristics. In: Balch CM, Houghton AN, Sober AJ (eds) Cutaneous melanoma, 4th edn. Quality Medical Publishing, Inc., St. Louis, Missouri, pp 135–162Google Scholar
  3. 3.
    Krementz ET, Feed RJ, Coleman WP 3rd et al (1982) Acral lentiginous melanoma. A clinicopathologic entity. Ann Surg 195:632–645PubMedCrossRefGoogle Scholar
  4. 4.
    Stalkup JR, Orengo IF, Katta R (2002) Controversies in acral lentiginous melanoma. Dermatol Surg 28:1051–1059 (discussion 9)PubMedCrossRefGoogle Scholar
  5. 5.
    Kuchelmeister C, Schaumburg-Lever G, Garbe C (2000) Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients. Br J Dermatol 143:275–280PubMedCrossRefGoogle Scholar
  6. 6.
    Green A, McCredie M, MacKie R et al (1999) A case-control study of melanomas of the soles and palms (Australia and Scotland). Cancer Causes Control 10:21–25PubMedCrossRefGoogle Scholar
  7. 7.
    Phan A, Touzet S, Dalle S et al (2007) Acral lentiginous melanoma: histopathological prognostic features of 121 cases. Br J Dermatol 157:311–318PubMedCrossRefGoogle Scholar
  8. 8.
    Briggs JC (1984) The role of trauma in the aetiology of malignant melanoma: a review article. Br J Plast Surg 37:514–516PubMedCrossRefGoogle Scholar
  9. 9.
    Curtin JA, Fridlyand J, Kageshita T et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135–2147PubMedCrossRefGoogle Scholar
  10. 10.
    Saldanha G, Potter L, Daforno P et al (2006) Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res 12:4499–4505PubMedCrossRefGoogle Scholar
  11. 11.
    Lang J, MacKie RM (2005) Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J Invest Dermatol 125:575–579PubMedCrossRefGoogle Scholar
  12. 12.
    Sasaki Y, Niu C, Makino R et al (2004) BRAF point mutations in primary melanoma show different prevalences by subtype. J Invest Dermatol 123:177–183PubMedCrossRefGoogle Scholar
  13. 13.
    Nagore E, Oliver V, Botella-Estrada R et al (2006) Clinicopathological analysis of 1571 cutaneous malignant melanomas in Valencia, Spain: factors related to tumour thickness. Acta Derm Venereol 86:50–56PubMedGoogle Scholar
  14. 14.
    Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 41:28–44PubMedCrossRefGoogle Scholar
  15. 15.
    Crowson AN, Magro CM, Barnhill RL et al (2003) Pathology. In: Balch CM, Houghton AN, Sober AJ (eds) Cutaneous melanoma, 4th edn. Quality Medical Publishing, Inc., St. Louis, Missouri, pp 171–206Google Scholar
  16. 16.
    Clemente CG, Mihm MC Jr, Bufalino R et al (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303–1310PubMedCrossRefGoogle Scholar
  17. 17.
    Phan A, Touzet S, Dalle S et al (2006) Acral lentiginous melanoma: a clinicoprognostic study of 126 cases. Br J Dermatol 155:561–569PubMedCrossRefGoogle Scholar
  18. 18.
    Ridgeway CA, Hieken TJ, Ronan SG et al (1995) Acral lentiginous melanoma. Arch Surg 130:88–92PubMedGoogle Scholar
  19. 19.
    Sutherland CM, Mather FJ, Muchmore JH et al (1993) Acral lentiginous melanoma. Am J Surg 166:64–67PubMedCrossRefGoogle Scholar
  20. 20.
    Balch CM, Buzaid AC, Soong SJ et al (2001) Final version of the American Joint Committee on cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635–3648PubMedGoogle Scholar
  21. 21.
    Edlundh-Rose E, Egyhazi S, Omholt K et al (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16:471–478PubMedCrossRefGoogle Scholar
  22. 22.
    Curtin JA, Busam K, Pinkel D et al (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340–4346PubMedCrossRefGoogle Scholar
  23. 23.
    Whiteman DC, Watt P, Purdie DM et al (2003) Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 95:806–812PubMedCrossRefGoogle Scholar
  24. 24.
    Whiteman DC, Parsons PG, Green AC (1998) p53 expression and risk factors for cutaneous melanoma: a case-control study. Int J Cancer 77:843–848PubMedCrossRefGoogle Scholar
  25. 25.
    Grange F, Chompret A, Guilloud-Bataille M et al (1995) Comparison between familial and nonfamilial melanoma in France. Arch Dermatol 131:1154–1159PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Eduardo Nagore
    • 1
    Email author
  • Carolina Pereda
    • 1
  • Rafael Botella-Estrada
    • 1
  • Celia Requena
    • 1
  • Carlos Guillén
    • 1
  1. 1.Department of DermatologyInstituto Valenciano de OncologíaValenciaSpain

Personalised recommendations